Maxcyte (MXCT) Non-Current Deferred Tax Liability (2024 - 2025)
Maxcyte (MXCT) posted quarterly Non-Current Deferred Tax Liability of $1.0 million for Q4 2025, down 18.48% year-over-year from $1.2 million in Q4 2024, and down 18.48% quarter-over-quarter from $1.2 million in Q4 2024.
Maxcyte (MXCT) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Maxcyte (MXCT) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $1.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability fell 18.48% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 18.48% YoY), while the FY2025 annual figure was $1.0 million, down 18.48% from the prior year.
- Non-Current Deferred Tax Liability fell to $1.0 million in Q4 2025 per MXCT's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.2 million in Q4 2024 and bottomed at $1.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.52 Bn | 193.92 Bn | 7.27 Bn |
| 2 | Stryker | 129.55 Bn | 126.07 Bn | 4.50 Bn |
| 3 | Medtronic | 119.60 Bn | 110.38 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.64 Bn | 73.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.33 Bn | 48.08 Bn | 1.35 Bn |
| 6 | Dexcom | 34.69 Bn | 32.74 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.10 Bn | 31.99 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.43 Bn | 23.11 Bn | 4.55 Bn |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn |
| 10 | Maxcyte | 147.95 Mn | 147.95 Mn | 5.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.01 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Dec 31, 2024 | 1.23 Mn |